510(k) · Cleared

Cleared

R&D Glu-Line Hematology Control

K034048510(k) TraditionalCleared Mar 10, 200471-day reviewClass I21 CFR 862.1660

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

R&D Systems, Inc. · JJX Single (Specified) Analyte Controls (Assayed And Unassayed)

Cleared on Mar 10, 2004 as substantially equivalent to K993321 (R&D Systems, Inc., 1999) after a 71-day review. Its family tree reaches back 3 generations to 1993.

Decided: Mar 10, 2004
Review: 71 days
Class: Class I
Product code: JJX
Recalls: None
Predicates: 1

Its longest line of descent runs back 3 generations to K934641 (1993). No later device cites it as a predicate yet.

By dateBy generation

Root · 3 generations backK934641 I-Stat Control Levels 1,2,3I-Stat Corp. · 1993
2 generations backK961195 Chem-Chex StatStreck Laboratories, Inc. · 1996
1 generation backK993321 R&D HGB/GLC Whole Blood ControlR&D Systems, Inc. · 1999
This deviceK034048 R&D Glu-Line Hematology ControlR&D Systems, Inc. · 2004

View FIG. 1 as a table

Line of descent and top descendants

Generation	Number	Device	Applicant	Decided	Recalls
−3	K934641	I-Stat Control Levels 1,2,3	I-Stat Corp.	1993	—
−2	K961195	Chem-Chex Stat	Streck Laboratories, Inc.	1996	—
−1	K993321	R&D HGB/GLC Whole Blood Control	R&D Systems, Inc.	1999	—
0 (this device)	K034048	R&D Glu-Line Hematology Control	R&D Systems, Inc.	2004	—

FIG. 1 — Lineage of K034048, 1993–2004Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JJX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Candidate predicates for a device like this, rankedin the report
Recall history across each candidate’s familyin the report

Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

Type	Number	Device	Applicant	Decided	Recalls
*	K993321	R&D HGB/GLC Whole Blood Control Summary page 1 …mixture. Device Class: Class II Predicate Device: R&D Sy:tems Glucose Hemoglobin Hematology Control, K993321 manufactured by R&D Syst.ems, Inc. 614 McKinley Place N.E., Minneapolis, MN 55413 Description: This control is a multilevel cont…	R&D Systems, Inc.	1999	—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

The line of descent spans 11 years and passes through 3 companies; a new generation was cleared every 3.5 years on median.
None of the 3 ancestors has a recall.

How does its category compare?

All JJX devices

JJX Single (Specified) Analyte Controls (Assayed And Unassayed): FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · JJX

2in 2017

2007high 24 (2010) · low 0 (2018)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JJX

31in 2016

2007high 80 (2009) · low 30 (2014)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · JJX

1in 2021

2007high 3 (2007) · low 0 (2009)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JJX

22in 2025

2007high 82 (2019) · low 0 (2008)2025

MAUDE reports naming product code JJX, not matched to any one device; reports are not rates.

View these four charts as a table

Year	Decisions	Median 510(k) review, days	Recalls (Class I)	MAUDE reports
2007	6	53	3	2
2008	8	52	3	0
2009	17	80	0	1
2010	24	80	3	6
2011	19	62	2	62
2012	15	40	0	32
2013	19	37	0	51
2014	22	30	1	48
2015	11	65	1	67
2016	6	31	2	37
2017	2	—	0	19
2018	0	—	2	35
2019	0	—	0	82
2020	0	—	0	77
2021	0	—	1	43
2022	0	—	0	24
2023	0	—	0	22
2024	0	—	0	30
2025	0	—	0	22
2026	0	—	0	—

What is it indicated for?

R&D GLU-LINE Hematology Control is a multilevel control that provides a means of measuring the linearity of glucose analyzers for glucose parameter determinations.

Indications for use as stated in the FDA summary.

https://510kreport.com/device/K034048 · printed Nov 4, 2026

Cite this page

510(k) Report. “K034048: R&D Glu-Line Hematology Control.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K034048

Report an extraction error

Are you the manufacturer?

Record history

FDA decision record loaded May 2, 2026
Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
Lineage and recalls computed Nov 3, 2026
Page last updated Nov 3, 2026